Catalogna v. Copley Pharmaceutical, Inc.

4 Mass. L. Rptr. 152
CourtMassachusetts Superior Court
DecidedAugust 11, 1995
DocketNo. 946662
StatusPublished

This text of 4 Mass. L. Rptr. 152 (Catalogna v. Copley Pharmaceutical, Inc.) is published on Counsel Stack Legal Research, covering Massachusetts Superior Court primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Catalogna v. Copley Pharmaceutical, Inc., 4 Mass. L. Rptr. 152 (Mass. Ct. App. 1995).

Opinion

Brassard, J.

The plaintiffs brought this action against Copley Pharmaceutical, Inc. (“Copley”), alleging damages recoverable under theories of strict product liability, negligence, breach of express warranty, breach of implied warranty, and fraud. The matter is before the Court on Copley’s motions to sever and dismiss. For reasons stated, the motions are denied.

BACKGROUND

The plaintiffs in this action live in Massachusetts, Pennsylvania, New Jersey, New York, Wisconsin, and Minnesota. Copley is organized under the laws of Delaware with a principal place of business in Massachusetts.

Copley is a manufacturer of Albuterol Sulfate Inhalation Solution 0.5% (“Albuterol”). Albuterol is a prescription drug intended to treat various respiratory illnesses, including asthma, and is used as a bronchodilator to assist in breathing. The plaintiffs allege that in order to increase production and profits, Copley engaged in “slipshod” practices and procedures with respect to the manufacture of Albuterol in violation of FDA regulations. These practices allowed the growth and presence of bacterial organisms in the drug that are harmful to human beings. In the course of Copley’s development and testing of Albuterol, its officers detected the presence of these organisms, but did not engage in further research, analysis and testing in order to prevent contamination. At the time, Copley was being sold to Hoechst Celanese Corporation, and the failure to act and to disclose the contamination was due to economic considerations. The plaintiffs further allege that Copley’s executives profited from their actions by hundreds of millions of dollars.

On or about January 5, 1994, Copley issued a nationwide recall of all lots of Albuterol because of contamination and the drug’s possible harm to users. This recall occurred after the FDA had discovered water quality problems in the manufacture of Al-buterol. The plaintiffs allege that their health was adversely affected by their use of the drug.

Copley has now brought a motion to sever, so that each plaintiffs case will be treated separately, and a motion to dismiss all suits except that of the Massachusetts plaintiff based on forum non conveniens.

DISCUSSION

1. Motion to Sever

Mass.RCiv.P. 20(a) governs permissive joinder of parties. It states: “All persons may join in one action as plaintiffs if they assert any right to reliefjointly, severally, or in the alternative, in respect of or arising out of the same transaction, occurrence, or series of transactions or occurrences and if any question of law or fact common to all these persons will arise in the action . . .”

[153]*153Mass.R.Civ.P. 20(b) states: “The court may make such orders as will prevent a party from being embarrassed, delayed, or put to expense by the inclusion of a party against whom he asserts no claim and who asserts no claim against him, and may order separate trials or make other orders to prevent delay or prejudice.” Similarly, Mass.R.Civ.P. 21 states: “. . . Parties may be dropped or added by order of the court or motion of any party ... at any stage of the action and on such terms as are just. Any claim against a party may be severed and proceeded with separately.”

Because Massachusetts courts have not closely examined Mass.R.Civ.P. 20(a), I turn to analysis of the analogous Federal Rule of Civil Procedure 20(a) for guidance. Federal courts have stated that this rule requires that for joinder of parties, two specific requisites must be met: a right to relief must be asserted by each plaintiff relating to or arising out of the same transaction or occurrence, and some question of law or fact common to all parties will arise in the action. League To Save Lake Tahoe v. Tahoe Reg. Plan. Agcy., 558 F.2d 914, 917 (9th Cir. 1977).

- The “transaction or occurrence test” of Rule 20 permits all reasonably related claims for relief by or against different parties to be tried in a single proceeding. Saval v. BL Ltd., 710 F.2d 1027, 1031 (4th Cir. 1983). Absolute identity of all events is unnecessary. Id. The purpose of the rule is to promote trial convenience and expedite the final determination of disputes, thereby preventing multiple lawsuits. Id. The impulse is toward entertaining the broadest possible scope of action consistent with fairness to the parties; joinder of parties is strongly encouraged. League to Save Lake Tahoe v. Tahoe Reg. Plan. Agcy., supra at 917, citing United Mine Workers of America v. Gibbs, 383 U.S. 715, 724 (1966). In ascertaining whether a particular factual situation constitutes a single transaction or occurrence for purposes of Rule 20, a case by case approach is generally practiced. Mosley v. General Motors Corporation, 497 F.2d 1330, 1333 (8th Cir. 1974). Generally, all “logically related” events entitling a person to institute a legal action are regarded as comprising a transaction or occurrence. Id.

In Saval, the United States Court of Appeals relied on District Court findings that plaintiffs, who alleged that they each purchased defective automobiles, glossed over the differences between the unique histories of the automobiles, and had not demonstrated that the problems with the cars resulted from a common defect. Saved v. BL Ltd., supra at 1031. Further, the cars were purchased at different times, were driven differently, and had different service histories. Id. Additionally, there was no proof of reliance on common misrepresentations or that each plaintiff received the same warranty. Id. The Court of Appeals found that, severance would be required in order to keep the facts straight pertaining to the separate automobiles and that allowing j oinder would mean that every purchaser of a product could join with every other purchaser, even if the products suffered from different defects, on the basis that a common warranty was given to each product. Id. The Court concluded that allowing joinder would not further judicial economy. Id. at 1032.

Similarly, the United States Court of Appeals stated that joinder was improper where multiple plaintiffs alleging asbestos poisoning from a ship failed to indicate in their complaint whether they were each injured while serving on the same vessel or during the same time periods, or whether they were injured by exposure to the same asbestos-containing products or equipment, or any specifications of the product or equipment to which they were exposed. Abdullah v. Acands, Inc., 30 F.3d 264, 628 n.5 (1st. Cir. 1994).

The United States Court of Appeals allowed joinder of plaintiffs who alleged that the defendant violated an agreement by approving land development projects and that construction on these projects would upset the ecology of the area. League to Save Lake Tahoe v. Tahoe Reg. Plan. Agency, supra at 917.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

United Mine Workers of America v. Gibbs
383 U.S. 715 (Supreme Court, 1966)
Abdullah v. ACands, Inc.
30 F.3d 264 (First Circuit, 1994)
In Re Bendectin Litigation.
857 F.2d 290 (Sixth Circuit, 1988)
W.R. Grace & Co. v. Hartford Accident & Indemnity Co.
555 N.E.2d 214 (Massachusetts Supreme Judicial Court, 1990)
New Amsterdam Casualty Co. v. Estes
228 N.E.2d 440 (Massachusetts Supreme Judicial Court, 1967)
Roddy & McNulty Insurance Agency, Inc. v. A. A. Proctor & Co.
452 N.E.2d 308 (Massachusetts Appeals Court, 1983)
Saval v. BL Ltd.
710 F.2d 1027 (Fourth Circuit, 1983)

Cite This Page — Counsel Stack

Bluebook (online)
4 Mass. L. Rptr. 152, Counsel Stack Legal Research, https://law.counselstack.com/opinion/catalogna-v-copley-pharmaceutical-inc-masssuperct-1995.